GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
Phase 2
Completed
- Conditions
- Lymphoma, Follicular
- Interventions
- Drug: OfatumumabDrug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: Prednisolone, Prednisone or equivalent
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00494780
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
Phase 1
Terminated
- Conditions
- Cancer
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00493818
- Locations
- 🇺🇸
GSK Investigational Site, Durham, North Carolina, United States
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Cervarix™ (HPV-16/18 L1 VLP AS04)
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00492544
- Locations
GSK Investigational Site
Month 30 & 42 Extension Studies of CRD-004 Primary Study
Phase 2
Completed
- Conditions
- Herpes Zoster
- Interventions
- Procedure: Blood sampling for assay of persistence of immunogenicity
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT00492648
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Phase 3
Completed
- Conditions
- TetanusDiphtheriaAcellular Pertussis
- Interventions
- Procedure: Taking of blood samplesBiological: BoostrixBiological: Adacel
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1954
- Registration Number
- NCT00489970
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1461
- Registration Number
- NCT00490568
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 239
- Registration Number
- NCT00490204
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
Phase 3
Completed
- Conditions
- Streptococcus Pneumoniae VaccinesInfections, Streptococcal
- Interventions
- Biological: SynflorixBiological: Infanrix hexaBiological: Rotarix
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 230
- Registration Number
- NCT00489554
- Locations
- 🇲🇽
GSK Investigational Site, Mexico, Mexico
Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden
Completed
- Conditions
- Rotavirus GastroenteritisInfections, Rotavirus
- Interventions
- Procedure: Blood sample collection
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 642
- Registration Number
- NCT00489567
Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers
Phase 1
Completed
- Conditions
- DyslipidaemiasHealthy Subjects
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT00488449
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath